Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.

Printer-friendly versionPrinter-friendly versionPDF versionPDF version
TitleDesign of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.
Publication TypeJournal Article
Year of Publication2021
AuthorsGuest, JD, Wang, R, Elkholy, KH, Chagas, A, Chao, KL, Cleveland, TE, Kim, YChang, Keck, Z-Y, Marin, A, Yunus, AS, Mariuzza, RA, Andrianov, AK, Toth, EA, Foung, SKH, Pierce, BG, Fuerst, TR
JournalProc Natl Acad Sci U S A
Date Published2021 Jan 19

Hepatitis C virus (HCV) is a major worldwide health burden, and a preventive vaccine is needed for global control or eradication of this virus. A substantial hurdle to an effective HCV vaccine is the high variability of the virus, leading to immune escape. The E1E2 glycoprotein complex contains conserved epitopes and elicits neutralizing antibody responses, making it a primary target for HCV vaccine development. However, the E1E2 transmembrane domains that are critical for native assembly make it challenging to produce this complex in a homogenous soluble form that is reflective of its state on the viral envelope. To enable rational design of an E1E2 vaccine, as well as structural characterization efforts, we have designed a soluble, secreted form of E1E2 (sE1E2). As with soluble glycoprotein designs for other viruses, it incorporates a scaffold to enforce assembly in the absence of the transmembrane domains, along with a furin cleavage site to permit native-like heterodimerization. This sE1E2 was found to assemble into a form closer to its expected size than full-length E1E2. Preservation of native structural elements was confirmed by high-affinity binding to a panel of conformationally specific monoclonal antibodies, including two neutralizing antibodies specific to native E1E2 and to its primary receptor, CD81. Finally, sE1E2 was found to elicit robust neutralizing antibodies in vivo. This designed sE1E2 can both provide insights into the determinants of native E1E2 assembly and serve as a platform for production of E1E2 for future structural and vaccine studies, enabling rational optimization of an E1E2-based antigen.

Alternate JournalProc Natl Acad Sci U S A
PubMed ID33431677